Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. [electronic resource]
Producer: 20150602Description: 109-15 p. digitalISSN:- 1879-355X
- Adrenal Cortex Hormones -- therapeutic use
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating -- therapeutic use
- Brain Neoplasms -- mortality
- Chemoradiotherapy -- adverse effects
- Chemotherapy, Adjuvant -- adverse effects
- DNA Methylation
- Dacarbazine -- analogs & derivatives
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Glioblastoma -- mortality
- Humans
- Karnofsky Performance Status
- Male
- O(6)-Methylguanine-DNA Methyltransferase -- metabolism
- Propensity Score
- Radiotherapy Dosage
- Regression Analysis
- Retrospective Studies
- Temozolomide
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.